Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial

Molly Katz, Leonard R. Derogatis, Ronald Ackerman, Parke Hedges, Lynna Lesko, Miguel Garcia, Michael Sand

Research output: Contribution to journalArticlepeer-review

122 Scopus citations


Introduction: Hypoactive Sexual Desire Disorder (HSDD) is characterized by low sexual desire that causes marked distress or interpersonal difficulty. Aim: The aim of this study was to assess the efficacy and safety of the 5-HT1A agonist/5-HT2A antagonist flibanserin in premenopausal women with HSDD. Methods: This was a randomized, placebo-controlled trial in which premenopausal women with HSDD (mean age: 36.6 years) were treated with flibanserin 100mg once daily at bedtime (qhs) (n=542) or placebo (n=545) for 24 weeks. Main Outcome Measures: Coprimary end points were the change from baseline to study end in Female Sexual Function Index (FSFI) desire domain score and in number of satisfying sexual events (SSE) over 28 days. Secondary end points included the change from baseline in FSFI total score, Female Sexual Distress Scale-Revised (FSDS-R) total score, and FSDS-R Item 13 score. Results: Compared with placebo, flibanserin led to increases in mean (standard deviation) SSE of 2.5 (4.6) vs. 1.5 (4.5), mean (standard error [SE]) FSFI desire domain score of 1.0 (0.1) vs. 0.7 (0.1), and mean (SE) FSFI total score of 5.3 (0.3) vs. 3.5 (0.3); and decreases in mean (SE) FSDS-R Item 13 score of -1.0 (0.1) vs. -0.7 (0.1) and mean (SE) FSDS-R total score of -9.4 (0.6) vs. -6.1 (0.6); all P≤0.0001. The most frequently reported adverse events in the flibanserin group were somnolence, dizziness, and nausea, with adverse events leading to discontinuation in 9.6% of women receiving flibanserin vs. 3.7% on placebo. Conclusion: In premenopausal women with HSDD, flibanserin 100mg qhs resulted in significant improvements in the number of SSE and sexual desire (FSFI desire domain score) vs. placebo. Flibanserin was associated with significant reductions in distress associated with sexual dysfunction (FSDS-R total score) and distress associated with low sexual desire (FSDS-R Item 13) vs. placebo. There were no significant safety concerns associated with the use of flibanserin for 24 weeks.

Original languageEnglish (US)
Pages (from-to)1807-1815
Number of pages9
JournalJournal of Sexual Medicine
Issue number7
StatePublished - Jul 2013


  • Distress
  • Flibanserin
  • HSDD
  • Hypoactive Sexual Desire Disorder
  • Patient-Reported Outcomes
  • Premenopausal Women

ASJC Scopus subject areas

  • Reproductive Medicine
  • Obstetrics and Gynecology
  • Urology


Dive into the research topics of 'Efficacy of flibanserin in women with hypoactive sexual desire disorder: Results from the BEGONIA trial'. Together they form a unique fingerprint.

Cite this